Valeria T Barletta1, Elena Herranz1, Costantina A Treaba1, Russell Ouellette2, Ambica Mehndiratta3, Marco L Loggia1, Eric C Klawiter4, Carolina Ionete5, Sloane A Jacob6, Caterina Mainero1. 1. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA. 2. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA/Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 3. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. 4. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA. 5. Multiple Sclerosis Center, UMass Memorial Medical Center, Worcester, MA, USA. 6. Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA/Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Activated microglia, which can be detected in vivo by 11C-PBR28 positron emission tomography (PET), represent a main component of MS pathology in the brain. Their role in the cerebellum is still unexplored, although cerebellar involvement in MS is frequent and accounts for disability progression. OBJECTIVES: We aimed at characterizing cerebellar neuroinflammation in MS patients compared to healthy subjects by combining 11C-PBR28 MRI-Positron Emission Tomography (MR-PET) with 7 Tesla (T) MRI and assessing its relationship with brain neuroinflammation and clinical outcome measures. METHODS: Twenty-eight MS patients and 16 healthy controls underwent 11C-PBR28 MR-PET to measure microglia activation in normal appearing cerebellum and lesions segmented from 7 T scans. Patients were evaluated using the Expanded Disability Status Scale and Symbol Digit Modalities Test. 11C-PBR28 binding was assessed in regions of interest using 60-90 minutes standardized uptake values normalized by a pseudo-reference region in the brain normal appearing white matter. Multilinear regression was used to compare tracer uptake in MS and healthy controls and assess correlations with clinical scores. RESULTS: In all cerebellar regions examined, MS patients showed abnormally increased tracer uptake, which correlated with cognitive and neurological disability. CONCLUSION: Neuroinflammation is widespread in the cerebellum of patients with MS and related to neurological disability and cognitive impairment.
BACKGROUND: Activated microglia, which can be detected in vivo by 11C-PBR28 positron emission tomography (PET), represent a main component of MS pathology in the brain. Their role in the cerebellum is still unexplored, although cerebellar involvement in MS is frequent and accounts for disability progression. OBJECTIVES: We aimed at characterizing cerebellar neuroinflammation in MSpatients compared to healthy subjects by combining 11C-PBR28 MRI-Positron Emission Tomography (MR-PET) with 7 Tesla (T) MRI and assessing its relationship with brain neuroinflammation and clinical outcome measures. METHODS: Twenty-eight MSpatients and 16 healthy controls underwent 11C-PBR28 MR-PET to measure microglia activation in normal appearing cerebellum and lesions segmented from 7 T scans. Patients were evaluated using the Expanded Disability Status Scale and Symbol Digit Modalities Test. 11C-PBR28 binding was assessed in regions of interest using 60-90 minutes standardized uptake values normalized by a pseudo-reference region in the brain normal appearing white matter. Multilinear regression was used to compare tracer uptake in MS and healthy controls and assess correlations with clinical scores. RESULTS: In all cerebellar regions examined, MSpatients showed abnormally increased tracer uptake, which correlated with cognitive and neurological disability. CONCLUSION: Neuroinflammation is widespread in the cerebellum of patients with MS and related to neurological disability and cognitive impairment.
Authors: David Izquierdo-Garcia; Adam E Hansen; Stefan Förster; Didier Benoit; Sylvia Schachoff; Sebastian Fürst; Kevin T Chen; Daniel B Chonde; Ciprian Catana Journal: J Nucl Med Date: 2014-10-02 Impact factor: 10.057
Authors: Eero Rissanen; Jouni Tuisku; Johanna Rokka; Teemu Paavilainen; Riitta Parkkola; Juha O Rinne; Laura Airas Journal: J Nucl Med Date: 2014-04-07 Impact factor: 10.057
Authors: Armin Kolb; Hans F Wehrl; Matthias Hofmann; Martin S Judenhofer; Lars Eriksson; Ralf Ladebeck; Matthias P Lichy; Larry Byars; Christian Michel; Heinz-Peter Schlemmer; Matthias Schmand; Claus D Claussen; Vesna Sossi; Bernd J Pichler Journal: Eur Radiol Date: 2012-03-27 Impact factor: 5.315
Authors: Alexandra Kutzelnigg; Claudia F Lucchinetti; Christine Stadelmann; Wolfgang Brück; Helmut Rauschka; Markus Bergmann; Manfred Schmidbauer; Joseph E Parisi; Hans Lassmann Journal: Brain Date: 2005-10-17 Impact factor: 13.501
Authors: William C Kreisl; Masahiro Fujita; Yota Fujimura; Nobuyo Kimura; Kimberly J Jenko; Pavitra Kannan; Jinsoo Hong; Cheryl L Morse; Sami S Zoghbi; Robert L Gladding; Steven Jacobson; Unsong Oh; Victor W Pike; Robert B Innis Journal: Neuroimage Date: 2009-12-04 Impact factor: 6.556
Authors: Brett A Parmenter; S Marc Testa; David J Schretlen; Bianca Weinstock-Guttman; Ralph H B Benedict Journal: J Int Neuropsychol Soc Date: 2009-10-02 Impact factor: 2.892
Authors: Katrin Weier; Iris K Penner; Stefano Magon; Michael Amann; Yvonne Naegelin; Michaela Andelova; Tobias Derfuss; Christoph Stippich; Ernst-Wilhelm Radue; Ludwig Kappos; Till Sprenger Journal: PLoS One Date: 2014-01-22 Impact factor: 3.240
Authors: Peter M Grace; Vivianne L Tawfik; Camilla I Svensson; Michael D Burton; Marco L Loggia; Mark R Hutchinson Journal: J Neurosci Date: 2020-11-25 Impact factor: 6.167
Authors: Nellwyn Hagan; John L Kane; Deepak Grover; Lisa Woodworth; Charlotte Madore; Jacqueline Saleh; Jose Sancho; Jinyu Liu; Yi Li; Jonathan Proto; Matija Zelic; Amy Mahan; Michael Kothe; Andrew A Scholte; Maria Fitzgerald; Barbara Gisevius; Aiden Haghikia; Oleg Butovsky; Dimitry Ofengeim Journal: Cell Death Dis Date: 2020-10-23 Impact factor: 8.469